The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).
Wěi Li(Shougang (China)), Caicun Zhou(Tongji University), Huijuan Wu(Henan Cancer Hospital), Kaihua Lu(Jiangsu Province Hospital), Kunyan Li(Central South University), Ping Sun(Yuhuangding Hospital), Xue Meng(Shandong Tumor Hospital), Xintian Qin(First Affiliated Hospital of Guangdong Pharmaceutical University), Nong Yang(Central South University), Wu Zhuang(Fujian Provincial Cancer Hospital), Yongsheng Wang(Xihua University), Huiwen Ma(Chongqing University), Ziping Wang(University of Science and Technology of China), Min Tao(Shanghai East Hospital), Xicheng Wang(Shandong University of Traditional Chinese Medicine), Yong Fang(Tongji Hospital), Jingxun Wu(First Affiliated Hospital of Xiamen University), Huijie Fan(Shanxi University), Yunpeng Liu(Shenyang Institute of Automation), Qitao Yu(Tumor Hospital of Guangxi Medical University)
Cited by 12
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
|Signal Transduction and Targeted Therapy|2021|909